ArticleAbdominal radiology (New York)2025
Comparison of MRI and prognostic features of intrahepatic cholangiocarcinoma between patients with and without hepatitis B virus infection.
Article in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the clinical, MRI, and prognostic features of intrahepatic cholangiocarcinoma (ICCA) between patients with and without hepatitis B virus (HBV) infection.
methodsWe retrospectively analyzed 211 patients with ICCA who underwent preoperative MRI and curative-intent surgical resection between 2015 and 2018. Two radiologists independently reviewed MRI features. Clinicopathologic and MRI characteristics were compared according to HBV status. Recurrence-free survival (RFS) and overall survival (OS) were assessed using the Kaplan-Meier method and log-rank test. Recurrence rates were compared according to tumor site, and logistic regression analysis was used to identify independent predictors of intrahepatic recurrence.
resultsAmong the 211 patients (mean age, 63.4 ± 10.5 years; 126 men), 81 (38.4%) were HBV-positive and 130 (61.6%) were HBV-negative. The purely mass-forming type of ICCA was more common in the HBV-positive group (91.4% vs. 76.9%; p = 0.007), whereas combined types were more frequent in the HBV-negative group. On MRI, peripheral tumor location was more frequent in the HBV-positive group (55.5% vs. 34.6%; p = 0.011), while bile duct invasion/dilatation (p < 0.001), secondary confluence involvement (p = 0.005), and periductal tumor infiltration (p = 0.030) were less common. Rim or non-rim arterial-phase enhancement (85.2% vs. 68.5%; p = 0.024) and radiologically-evident cirrhosis (19.8% vs. 8.5%; p = 0.017) were more frequent in HBV-positive patients. Although RFS and OS did not significantly differ between the groups (p ≥ 0.327), the intrahepatic recurrence rate was significantly higher in the HBV-positive group (37.0% vs. 23.1%; p = 0.029). HBV positivity was also identified as an independent predictor of intrahepatic recurrence (odds ratio, 1.93; p = 0.047).
conclusionHBV-associated ICCA demonstrates distinct MRI features and is associated with a higher rate of intrahepatic recurrence following curative resection.
Indexed as
Identifiers
40459595What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.